 | • レポートコード：MR2211MG10959 • 出版社/出版日：Market Monitor Global / 2022年11月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2-3日） • 産業分類：医療 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥625,300 (USD4,225) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は次の情報を含め、認知症治療のグローバル市場規模と予測を記載しています。・認知症治療のグローバル市場：売上、2017年-2022年、2023年-2028年 ・認知症治療のグローバル市場：販売量、2017年-2022年、2023年-2028年 ・世界のトップ5企業、2021年 認知症治療のグローバル市場規模は2021年に000Mドルと評価され、予測期間中に000％のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「抗てんかん薬型認知症治療」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。 認知症治療のグローバル主要企業は、Eli Lilly and Company、 AstraZeneca、 Bristol-Myers Squibb、 Pfizer、 Minerva Neurosciences、 Intra-Cellular Therapies、 Avineuro Pharmaceuticals、 SyneuRx、 Lundbeck、 AB Science SA、 AbbVie Inc、 CHA Bio & Diostech Co Ltd、 Echo Pharmaceuticals BV、 Eisai Co Ltd、 GlaxoSmithKline Plc、 Grifols SA、 Immungenetics AG、 Otsuka Holdings Co Ltdなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。 マーケットモニターグローバル（MMG）社は、認知症治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の認知症治療市場：タイプ別、2017年-2022年、2023年-2028年 世界の認知症治療市場：タイプ別市場シェア、2021年 ・抗てんかん薬型認知症治療、抗精神病薬型認知症治療 世界の認知症治療市場：用途別、2017年-2022年、2023年-2028年 世界の認知症治療市場：用途別市場シェア、2021年 ・病院薬局、専門クリニック、薬局、その他 世界の認知症治療市場：地域・国別、2017年-2022年、2023年-2028年 世界の認知症治療市場：地域別市場シェア、2021年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における認知症治療のグローバル売上、2017年-2022年 ・主要企業における認知症治療のグローバル売上シェア、2021年 ・主要企業における認知症治療のグローバル販売量、2017年-2022年 ・主要企業における認知症治療のグローバル販売量シェア、2021年 さらに、当レポートは主要企業のプロファイルを提示します。 Eli Lilly and Company、 AstraZeneca、 Bristol-Myers Squibb、 Pfizer、 Minerva Neurosciences、 Intra-Cellular Therapies、 Avineuro Pharmaceuticals、 SyneuRx、 Lundbeck、 AB Science SA、 AbbVie Inc、 CHA Bio & Diostech Co Ltd、 Echo Pharmaceuticals BV、 Eisai Co Ltd、 GlaxoSmithKline Plc、 Grifols SA、 Immungenetics AG、 Otsuka Holdings Co Ltd ************************************************************* ・調査・分析レポートの概要 認知症治療市場の定義 市場セグメント 世界の認知症治療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の認知症治療市場規模 世界の認知症治療市場規模：2021年 VS 2028年 世界の認知症治療市場規模と予測 2017年-2028年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの認知症治療の売上 グローバルトップ3およびトップ5企業、2021年売上ベース グローバル企業の認知症治療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：抗てんかん薬型認知症治療、抗精神病薬型認知症治療 認知症治療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院薬局、専門クリニック、薬局、その他 認知症治療の用途別グローバル売上・予測 ・地域別市場分析 地域別認知症治療市場規模 2021年と2028年 地域別認知症治療売上・予測 北米市場 - アメリカの認知症治療市場規模2017年-2028年 - カナダの認知症治療市場規模2017年-2028年 - メキシコの認知症治療市場規模2017年-2028年 ヨーロッパ市場 - ドイツの認知症治療市場規模2017年-2028年 - フランスの認知症治療市場規模2017年-2028年 - イギリスの認知症治療市場規模2017年-2028年 - イタリアの認知症治療市場規模2017年-2028年 - ロシアの認知症治療市場規模2017年-2028年 アジア市場 - 中国の認知症治療市場規模2017年-2028年 - 日本の認知症治療市場規模2017年-2028年 - 韓国の認知症治療市場規模2017年-2028年 - 東南アジアの認知症治療市場規模2017年-2028年 - インドの認知症治療市場規模2017年-2028年 南米市場 - ブラジルの認知症治療市場規模2017年-2028年 - アルゼンチンの認知症治療市場規模2017年-2028年 中東・アフリカ市場 - トルコの認知症治療市場規模2017年-2028年 - イスラエルの認知症治療市場規模2017年-2028年 - サウジアラビアの認知症治療市場規模2017年-2028年 - UAEの認知症治療市場規模2017年-2028年 ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Eli Lilly and Company、 AstraZeneca、 Bristol-Myers Squibb、 Pfizer、 Minerva Neurosciences、 Intra-Cellular Therapies、 Avineuro Pharmaceuticals、 SyneuRx、 Lundbeck、 AB Science SA、 AbbVie Inc、 CHA Bio & Diostech Co Ltd、 Echo Pharmaceuticals BV、 Eisai Co Ltd、 GlaxoSmithKline Plc、 Grifols SA、 Immungenetics AG、 Otsuka Holdings Co Ltd ... |
This report contains market size and forecasts of Cognitive Impairment Disorders Treatment in Global, including the following market information:
Global Cognitive Impairment Disorders Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cognitive Impairment Disorders Treatment market was valued at US$ million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Antiepileptic Drugs Cognitive Impairment Disorders Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cognitive Impairment Disorders Treatment include Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Minerva Neurosciences, Intra-Cellular Therapies, Avineuro Pharmaceuticals, SyneuRx and Lundbeck, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cognitive Impairment Disorders Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cognitive Impairment Disorders Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cognitive Impairment Disorders Treatment Market Segment Percentages, by Type, 2021 (%)
Antiepileptic Drugs Cognitive Impairment Disorders Treatment
Antipsychotics Drugs Cognitive Impairment Disorders Treatment
Global Cognitive Impairment Disorders Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cognitive Impairment Disorders Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Specialty Clinics
Retail Pharmacies
Others
Global Cognitive Impairment Disorders Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cognitive Impairment Disorders Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cognitive Impairment Disorders Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cognitive Impairment Disorders Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Pfizer
Minerva Neurosciences
Intra-Cellular Therapies
Avineuro Pharmaceuticals
SyneuRx
Lundbeck
AB Science SA
AbbVie Inc
CHA Bio & Diostech Co Ltd
Echo Pharmaceuticals BV
Eisai Co Ltd
GlaxoSmithKline Plc
Grifols SA
Immungenetics AG
Otsuka Holdings Co Ltd
Merck & Co Inc
Kyowa Hakko Kirin Co Ltd
1 Introduction to Research & Analysis Reports
1.1 Cognitive Impairment Disorders Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cognitive Impairment Disorders Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cognitive Impairment Disorders Treatment Overall Market Size
2.1 Global Cognitive Impairment Disorders Treatment Market Size: 2021 VS 2028
2.2 Global Cognitive Impairment Disorders Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Cognitive Impairment Disorders Treatment Players in Global Market
3.2 Top Global Cognitive Impairment Disorders Treatment Companies Ranked by Revenue
3.3 Global Cognitive Impairment Disorders Treatment Revenue by Companies
3.4 Top 3 and Top 5 Cognitive Impairment Disorders Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Cognitive Impairment Disorders Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cognitive Impairment Disorders Treatment Players in Global Market
3.6.1 List of Global Tier 1 Cognitive Impairment Disorders Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Cognitive Impairment Disorders Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type – Global Cognitive Impairment Disorders Treatment Market Size Markets, 2021 & 2028
4.1.2 Antiepileptic Drugs Cognitive Impairment Disorders Treatment
4.1.3 Antipsychotics Drugs Cognitive Impairment Disorders Treatment
4.2 By Type – Global Cognitive Impairment Disorders Treatment Revenue & Forecasts
4.2.1 By Type – Global Cognitive Impairment Disorders Treatment Revenue, 2017-2022
4.2.2 By Type – Global Cognitive Impairment Disorders Treatment Revenue, 2023-2028
4.2.3 By Type – Global Cognitive Impairment Disorders Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Cognitive Impairment Disorders Treatment Market Size, 2021 & 2028
5.1.2 Hospital Pharmacies
5.1.3 Specialty Clinics
5.1.4 Retail Pharmacies
5.1.5 Others
5.2 By Application – Global Cognitive Impairment Disorders Treatment Revenue & Forecasts
5.2.1 By Application – Global Cognitive Impairment Disorders Treatment Revenue, 2017-2022
5.2.2 By Application – Global Cognitive Impairment Disorders Treatment Revenue, 2023-2028
5.2.3 By Application – Global Cognitive Impairment Disorders Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region – Global Cognitive Impairment Disorders Treatment Market Size, 2021 & 2028
6.2 By Region – Global Cognitive Impairment Disorders Treatment Revenue & Forecasts
6.2.1 By Region – Global Cognitive Impairment Disorders Treatment Revenue, 2017-2022
6.2.2 By Region – Global Cognitive Impairment Disorders Treatment Revenue, 2023-2028
6.2.3 By Region – Global Cognitive Impairment Disorders Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country – North America Cognitive Impairment Disorders Treatment Revenue, 2017-2028
6.3.2 US Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.3.3 Canada Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.3.4 Mexico Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country – Europe Cognitive Impairment Disorders Treatment Revenue, 2017-2028
6.4.2 Germany Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.4.3 France Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.4.4 U.K. Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.4.5 Italy Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.4.6 Russia Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.4.8 Benelux Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region – Asia Cognitive Impairment Disorders Treatment Revenue, 2017-2028
6.5.2 China Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.5.3 Japan Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.5.4 South Korea Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.5.6 India Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country – South America Cognitive Impairment Disorders Treatment Revenue, 2017-2028
6.6.2 Brazil Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.6.3 Argentina Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Cognitive Impairment Disorders Treatment Revenue, 2017-2028
6.7.2 Turkey Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.7.3 Israel Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Cognitive Impairment Disorders Treatment Market Size, 2017-2028
6.7.5 UAE Cognitive Impairment Disorders Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Eli Lilly and Company
7.1.1 Eli Lilly and Company Corporate Summary
7.1.2 Eli Lilly and Company Business Overview
7.1.3 Eli Lilly and Company Cognitive Impairment Disorders Treatment Major Product Offerings
7.1.4 Eli Lilly and Company Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.1.5 Eli Lilly and Company Key News
7.2 AstraZeneca
7.2.1 AstraZeneca Corporate Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Cognitive Impairment Disorders Treatment Major Product Offerings
7.2.4 AstraZeneca Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.2.5 AstraZeneca Key News
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Corporate Summary
7.3.2 Bristol-Myers Squibb Business Overview
7.3.3 Bristol-Myers Squibb Cognitive Impairment Disorders Treatment Major Product Offerings
7.3.4 Bristol-Myers Squibb Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.3.5 Bristol-Myers Squibb Key News
7.4 Pfizer
7.4.1 Pfizer Corporate Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Cognitive Impairment Disorders Treatment Major Product Offerings
7.4.4 Pfizer Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.4.5 Pfizer Key News
7.5 Minerva Neurosciences
7.5.1 Minerva Neurosciences Corporate Summary
7.5.2 Minerva Neurosciences Business Overview
7.5.3 Minerva Neurosciences Cognitive Impairment Disorders Treatment Major Product Offerings
7.5.4 Minerva Neurosciences Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.5.5 Minerva Neurosciences Key News
7.6 Intra-Cellular Therapies
7.6.1 Intra-Cellular Therapies Corporate Summary
7.6.2 Intra-Cellular Therapies Business Overview
7.6.3 Intra-Cellular Therapies Cognitive Impairment Disorders Treatment Major Product Offerings
7.6.4 Intra-Cellular Therapies Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.6.5 Intra-Cellular Therapies Key News
7.7 Avineuro Pharmaceuticals
7.7.1 Avineuro Pharmaceuticals Corporate Summary
7.7.2 Avineuro Pharmaceuticals Business Overview
7.7.3 Avineuro Pharmaceuticals Cognitive Impairment Disorders Treatment Major Product Offerings
7.7.4 Avineuro Pharmaceuticals Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.7.5 Avineuro Pharmaceuticals Key News
7.8 SyneuRx
7.8.1 SyneuRx Corporate Summary
7.8.2 SyneuRx Business Overview
7.8.3 SyneuRx Cognitive Impairment Disorders Treatment Major Product Offerings
7.8.4 SyneuRx Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.8.5 SyneuRx Key News
7.9 Lundbeck
7.9.1 Lundbeck Corporate Summary
7.9.2 Lundbeck Business Overview
7.9.3 Lundbeck Cognitive Impairment Disorders Treatment Major Product Offerings
7.9.4 Lundbeck Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.9.5 Lundbeck Key News
7.10 AB Science SA
7.10.1 AB Science SA Corporate Summary
7.10.2 AB Science SA Business Overview
7.10.3 AB Science SA Cognitive Impairment Disorders Treatment Major Product Offerings
7.10.4 AB Science SA Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.10.5 AB Science SA Key News
7.11 AbbVie Inc
7.11.1 AbbVie Inc Corporate Summary
7.11.2 AbbVie Inc Business Overview
7.11.3 AbbVie Inc Cognitive Impairment Disorders Treatment Major Product Offerings
7.11.4 AbbVie Inc Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.11.5 AbbVie Inc Key News
7.12 CHA Bio & Diostech Co Ltd
7.12.1 CHA Bio & Diostech Co Ltd Corporate Summary
7.12.2 CHA Bio & Diostech Co Ltd Business Overview
7.12.3 CHA Bio & Diostech Co Ltd Cognitive Impairment Disorders Treatment Major Product Offerings
7.12.4 CHA Bio & Diostech Co Ltd Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.12.5 CHA Bio & Diostech Co Ltd Key News
7.13 Echo Pharmaceuticals BV
7.13.1 Echo Pharmaceuticals BV Corporate Summary
7.13.2 Echo Pharmaceuticals BV Business Overview
7.13.3 Echo Pharmaceuticals BV Cognitive Impairment Disorders Treatment Major Product Offerings
7.13.4 Echo Pharmaceuticals BV Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.13.5 Echo Pharmaceuticals BV Key News
7.14 Eisai Co Ltd
7.14.1 Eisai Co Ltd Corporate Summary
7.14.2 Eisai Co Ltd Business Overview
7.14.3 Eisai Co Ltd Cognitive Impairment Disorders Treatment Major Product Offerings
7.14.4 Eisai Co Ltd Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.14.5 Eisai Co Ltd Key News
7.15 GlaxoSmithKline Plc
7.15.1 GlaxoSmithKline Plc Corporate Summary
7.15.2 GlaxoSmithKline Plc Business Overview
7.15.3 GlaxoSmithKline Plc Cognitive Impairment Disorders Treatment Major Product Offerings
7.15.4 GlaxoSmithKline Plc Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.15.5 GlaxoSmithKline Plc Key News
7.16 Grifols SA
7.16.1 Grifols SA Corporate Summary
7.16.2 Grifols SA Business Overview
7.16.3 Grifols SA Cognitive Impairment Disorders Treatment Major Product Offerings
7.16.4 Grifols SA Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.16.5 Grifols SA Key News
7.17 Immungenetics AG
7.17.1 Immungenetics AG Corporate Summary
7.17.2 Immungenetics AG Business Overview
7.17.3 Immungenetics AG Cognitive Impairment Disorders Treatment Major Product Offerings
7.17.4 Immungenetics AG Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.17.5 Immungenetics AG Key News
7.18 Otsuka Holdings Co Ltd
7.18.1 Otsuka Holdings Co Ltd Corporate Summary
7.18.2 Otsuka Holdings Co Ltd Business Overview
7.18.3 Otsuka Holdings Co Ltd Cognitive Impairment Disorders Treatment Major Product Offerings
7.18.4 Otsuka Holdings Co Ltd Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.18.5 Otsuka Holdings Co Ltd Key News
7.19 Merck & Co Inc
7.19.1 Merck & Co Inc Corporate Summary
7.19.2 Merck & Co Inc Business Overview
7.19.3 Merck & Co Inc Cognitive Impairment Disorders Treatment Major Product Offerings
7.19.4 Merck & Co Inc Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.19.5 Merck & Co Inc Key News
7.20 Kyowa Hakko Kirin Co Ltd
7.20.1 Kyowa Hakko Kirin Co Ltd Corporate Summary
7.20.2 Kyowa Hakko Kirin Co Ltd Business Overview
7.20.3 Kyowa Hakko Kirin Co Ltd Cognitive Impairment Disorders Treatment Major Product Offerings
7.20.4 Kyowa Hakko Kirin Co Ltd Cognitive Impairment Disorders Treatment Revenue in Global Market (2017-2022)
7.20.5 Kyowa Hakko Kirin Co Ltd Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer